$ARES has released its earnings report for Q4 and year-end 2024, showcasing a strong performance with notable increases in assets under management (AUM) and fee-related earnings. AUM rose by 16% to over $484 billion, while management fees climbed to a record $781 million. The firm has increased its quarterly dividend by 20%, reflecting confidence in future growth. However, a dynamic market and potential regulatory changes pose risks. Future opportunities include expanding direct lending strategies and acquisitions. 🌐💵 Check details at valueverge.com/ARES.

$EQNR has released its latest earnings report, showcasing a strong quarterly performance. Here's a quick look at the key stats: Return on Capital Employed is at 21%, with cash flow from operations hitting $18 billion. Risks include fluctuating energy prices and geopolitical tensions, but the company remains committed to delivering sustainable growth and competitive returns.

🚨 $GSK announces its 2024 earnings results, showcasing a sales increase of 8% to over £31 billion, driven by specialty medicines and significant profit growth📈. Core operating profit rose by 13%, with core EPS up 12%. However, vaccine sales faced challenges, impacting short-term growth forecasts. 💉 The outlook for 2025 anticipates continued robust growth, particularly in specialty medicines, with five new product approvals expected. 📊 For more details, visit valueverge.com/GSK.

$EMR has released earnings for Q4 and the full year 2024, announcing a robust performance with underlying sales growth of 6% and an adjusted EPS of $5.49, reflecting a strong operational execution. Risks remain with ongoing challenges in the discrete markets, while opportunities include a significant backlog of $7.2 billion and a strategic proposal to acquire the remaining shares of AspenTech, aiming for portfolio transformation. Future guidance suggests continued mid-single-digit growth in 2025. 📈💰 Full details at valueverge.com/EMR.

$ITW has released its Q4 earnings report, showing a GAAP EPS of $2.54, marking a 7% improvement. Organic revenue fell 0.5%, better than expectations. Key highlights include a record operating margin of 26.2%, driven by strong operational execution.

$MCK has released its fiscal Q4 earnings report. Key stats show a 12% revenue growth to $309 billion and adjusted EPS at $27.44 (+6%). Risks include increased operating expenses and a reserve for environmental matters. Highlights include a strong outlook for fiscal 2025 with anticipated revenue growth of 15%-17% 🚀.

$SAN has released its earnings report for 2024, showing a record profit of €12.6 billion, indicating strong revenue growth and customer acquisition. Despite challenges, the solid balance sheet is highlighted by a CET1 ratio of 12.8%. 📈

$FI has released its Q4 2024 earnings report, showcasing strong results. Key highlights include adjusted EPS up 17% to $8.80 and adjusted revenue growth of 7%. Risks involve currency fluctuations, particularly in Argentina, but financial health appears robust with $5.2 billion in free cash flow returned to shareholders. Looking ahead, opportunities for growth exist with new offerings like Cash Flow Central and strategic partnerships. ⚡📈 Investors are encouraged to check details in valueverge.com/FI.

$TTE has released its latest earnings report, showcasing a solid performance. Notable highlights include a significant increase in net income to $18.3 billion and a robust return on equity of 15.8%. However, risks include a continued decline in refining margins and increased operational costs.

$UBER has released its earnings report for Q4 2024. Key highlights: Gross bookings grew 21% YoY, with adjusted EBITDA rising 60%. The Uber One membership program saw a significant increase in users, indicating strong demand. However, FX headwinds may affect Q1 growth guidance, projected between 17-21%. 🚗💰 Looking ahead, risks include currency fluctuations and competition in AVs. Despite these challenges, Uber remains optimistic about long-term growth and profitability. Check details at valueverge.com/UBER.